Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Epicriptine is a small molecule nootropic and peptide ergot alkaloid of the ergoline class, also known as beta-dihydroergocryptine. It constitutes one third of the mixture known as dihydroergocryptine, with the other two thirds being alpha-dihydroergocryptine. The primary clinical use for epicriptine is in individuals over sixty who manifest signs and symptoms of an idiopathic decline in mental capacity, such as cognitive impairment. Its mechanism of action is mainly due to agonistic activity on dopamine receptors, contributing to its effects on cognition and mood. Epicriptine is a component of ergoloid mesylate preparations that have been used for symptomatic relief in age-related cognitive decline[1][2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on epicriptine.